YBX1 and hepatocellular carcinoma: Xu et al. found that circRNA-SORE was upregated in sorafenib drug-resistant hepatocellular carcinoma cells, which blocked PRP19-mediated YBX1 degradation by binding to cytoplasmic oncogenic protein YBX1.